Status: Recruiting
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism
This is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending and multiple dose study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CITY-FXI in healthy adults, adults with Factor V Leiden (FVL) or prothrombin G20210A mutation, and adults with a history of provoked venous thromboembolism (VTE).
Participants needed: 182
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: City TherapeuticsUpdated: Sep 25, 2026Locations: 1
Eligibility criteria
Males and women of non-childbearing potential (WONCBP) aged 18 to 45 years (incl... [+6]
Any clinically significant systemic disease or disorder, including but not limit... [+4]